Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Tracking and quantifying polymer therapeutic distribution on a cellular level using 3D dSTORM.

Hartley JM, Zhang R, Gudheti M, Yang J, Kopeček J.

J Control Release. 2016 Jun 10;231:50-9. doi: 10.1016/j.jconrel.2016.02.005. Epub 2016 Feb 16.

2.

Electrochemistry and speciation of Au(+) in a deep eutectic solvent: growth and morphology of galvanic immersion coatings.

Ballantyne AD, Forrest GC, Frisch G, Hartley JM, Ryder KS.

Phys Chem Chem Phys. 2015 Nov 11;17(45):30540-50. doi: 10.1039/c5cp05748e.

PMID:
26523806
3.
4.

Super-Resolution Imaging and Quantitative Analysis of Membrane Protein/Lipid Raft Clustering Mediated by Cell-Surface Self-Assembly of Hybrid Nanoconjugates.

Hartley JM, Chu TW, Peterson EM, Zhang R, Yang J, Harris J, Kopeček J.

Chembiochem. 2015 Aug 17;16(12):1725-9. doi: 10.1002/cbic.201500278. Epub 2015 Jul 2.

5.

Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.

Zhang R, Yang J, Chu TW, Hartley JM, Kopeček J.

Adv Healthc Mater. 2015 May;4(7):1054-65. doi: 10.1002/adhm.201400679. Epub 2015 Jan 21.

6.

EXAFS study into the speciation of metal salts dissolved in ionic liquids and deep eutectic solvents.

Hartley JM, Ip CM, Forrest GC, Singh K, Gurman SJ, Ryder KS, Abbott AP, Frisch G.

Inorg Chem. 2014 Jun 16;53(12):6280-8. doi: 10.1021/ic500824r. Epub 2014 Jun 5.

PMID:
24897923
7.

Immunogenicity of coiled-coil based drug-free macromolecular therapeutics.

Kverka M, Hartley JM, Chu TW, Yang J, Heidchen R, Kopeček J.

Biomaterials. 2014 Jul;35(22):5886-96. doi: 10.1016/j.biomaterials.2014.03.063. Epub 2014 Apr 22.

8.

Ultrasonic gene and drug delivery using eLiposomes.

Javadi M, Pitt WG, Tracy CM, Barrow JR, Willardson BM, Hartley JM, Tsosie NH.

J Control Release. 2013 Apr 10;167(1):92-100. doi: 10.1016/j.jconrel.2013.01.009. Epub 2013 Jan 23.

PMID:
23352908
9.

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses.

Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR.

BMC Cancer. 2012 Nov 21;12:536. doi: 10.1186/1471-2407-12-536.

10.

Encapsulating nanoemulsions inside eLiposomes for ultrasonic drug delivery.

Javadi M, Pitt WG, Belnap DM, Tsosie NH, Hartley JM.

Langmuir. 2012 Oct 16;28(41):14720-9. doi: 10.1021/la303464v. Epub 2012 Oct 4.

PMID:
22989347
11.

Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.

Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW.

Phytomedicine. 2012 May 15;19(7):618-24. doi: 10.1016/j.phymed.2012.02.003. Epub 2012 Mar 6.

PMID:
22402246
12.

Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.

Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos K, Burgess-Brown NA, Swift LP, Enzlin JH, Schofield CJ, Gileadi O, Hartley JA, McHugh PJ.

Genes Dev. 2011 Sep 1;25(17):1859-70. doi: 10.1101/gad.15699211.

13.

Measurement of DNA damage in individual cells using the Single Cell Gel Electrophoresis (Comet) assay.

Hartley JM, Spanswick VJ, Hartley JA.

Methods Mol Biol. 2011;731:309-20. doi: 10.1007/978-1-61779-080-5_25.

PMID:
21516417
14.

Preliminary results of combining low frequency low intensity ultrasound and liposomal drug delivery to treat tumors in rats.

Pitt WG, Husseini GA, Roeder BL, Dickinson DJ, Warden DR, Hartley JM, Jones PW.

J Nanosci Nanotechnol. 2011 Mar;11(3):1866-70.

PMID:
21449322
15.

SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

Hartley JA, Hamaguchi A, Coffils M, Martin CR, Suggitt M, Chen Z, Gregson SJ, Masterson LA, Tiberghien AC, Hartley JM, Pepper C, Lin TT, Fegan C, Thurston DE, Howard PW.

Cancer Res. 2010 Sep 1;70(17):6849-58. doi: 10.1158/0008-5472.CAN-10-0790. Epub 2010 Jul 26.

16.

Measurement of DNA interstrand crosslinking in naked DNA using gel-based methods.

Kiakos K, Hartley JM, Hartley JA.

Methods Mol Biol. 2010;613:283-302. doi: 10.1007/978-1-60327-418-0_18.

PMID:
19997891
17.

Measurement of DNA interstrand crosslinking in individual cells using the Single Cell Gel Electrophoresis (Comet) assay.

Spanswick VJ, Hartley JM, Hartley JA.

Methods Mol Biol. 2010;613:267-82. doi: 10.1007/978-1-60327-418-0_17.

PMID:
19997890
18.

Functionalised cyclopentadienyl titanium compounds as potential anticancer drugs.

Allen OR, Gott AL, Hartley JA, Hartley JM, Knox RJ, McGowan PC.

Dalton Trans. 2007 Nov 21;(43):5082-90. Epub 2007 Sep 19.

PMID:
17992293
19.

Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship.

Rachid Z, Brahimi F, Qiu Q, Williams C, Hartley JM, Hartley JA, Jean-Claude BJ.

J Med Chem. 2007 May 31;50(11):2605-8. Epub 2007 May 2.

PMID:
17472358
20.

Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.

Hochhauser D, Kotecha M, O'hare C, Morris PJ, Hartley JM, Taherbhai Z, Harris D, Forni C, Mantovani R, Lee M, Hartley JA.

Mol Cancer Ther. 2007 Jan;6(1):346-54.

21.

Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay.

Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA.

Clin Cancer Res. 1999 Mar;5(3):507-12.

22.

Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay.

Spanswick VJ, Hartley JM, Ward TH, Hartley JA.

Methods Mol Med. 1999;28:143-54. doi: 10.1385/1-59259-687-8:143.

PMID:
21374035
23.

Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.

Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.

Clin Cancer Res. 1997 Sep;3(9):1507-18.

24.

The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.

Singer JM, Hartley JM, Brennan C, Nicholson PW, Souhami RL.

Br J Cancer. 1998 Mar;77(6):978-84.

25.

Metabolism of ifosfamide during a 3 day infusion.

Hartley JM, Hansen L, Harland SJ, Nicholson PW, Pasini F, Souhami RL.

Br J Cancer. 1994 May;69(5):931-6.

26.

Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolism.

Zucchetti M, Zambetti M, Hartley JM, D'Incalci M.

Ann Oncol. 1993 Dec;4(10):895. No abstract available.

PMID:
8117611
27.

Pharmacokinetics of 10-ethyl-10-deaza-aminopterin, edatrexate, given weekly for non-small-cell lung cancer.

Hartley JM, Nicholson PW, Allen R, Lamond P, Harland SJ, Souhami RL.

Cancer Chemother Pharmacol. 1993;31(4):328-32.

PMID:
8380758
28.

Physicians' forum: medical direction and accountability for EMS advanced life support care in rural North Carolina.

Hartley JM, Landis SS, Allison EJ Jr.

N C Med J. 1985 May;46(5):271-3. No abstract available.

PMID:
3858678
29.

Transoesophageal cardiac pacing.

Hartley JM.

Anaesthesia. 1982 Feb;37(2):192-4.

30.
31.

A case of blackwater fever.

Jones BV, Hartley JM, Robertson JR.

J R Nav Med Serv. 1968 Summer;54(2):131-4. No abstract available.

PMID:
5661211

Supplemental Content

Loading ...
Support Center